Biovie Inc. SEC filings BIVI
Biovie Inc. has 507 filings in SEC EDGAR's recent list, going back to Jul 2, 2013. Its latest annual report, Form 10-K, was filed on Aug 13, 2026 for the period ended Jun 30, 2026. The latest quarterly report (Form 10-Q) was filed on May 11, 2026, covering the quarter ended Mar 31, 2026. The most recent current report (Form 8-K) was filed on Sep 14, 2026 (material agreement). The company's fiscal year ends on June 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jun 29, 2026 | — |
| DRS | Filing | Jun 11, 2026 | — |
| EFFECT | Filing | Nov 18, 2025 | — |
| POS EX | Filing | Oct 6, 2025 | — |
| EFFECT | Filing | Aug 7, 2025 | — |
| CERT | Filing | Aug 7, 2025 | — |
| 8-A12B | Form 8-a12b | Aug 7, 2025 | — |
| CORRESP | Letter to the SEC | Aug 4, 2025 | — |
| CORRESP | Letter to the SEC | Aug 4, 2025 | — |
| CORRESP | Letter to the SEC | Jul 24, 2025 | — |
| CORRESP | Letter to the SEC | Jul 24, 2025 | — |
| CORRESP | Letter to the SEC | Jul 22, 2025 | — |
| CORRESP | Letter to the SEC | Jul 22, 2025 | — |
| UPLOAD | Letter from the SEC | May 20, 2025 | — |
| DRS | Filing | May 15, 2025 | — |
| DRSLTR | Filing | May 14, 2025 | — |
| 1-A | Filing | Dec 31, 2024 | — |
| EFFECT | Filing | Dec 2, 2024 | — |
| CORRESP | Letter to the SEC | Nov 29, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 26, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 5, 2024 | — |
| CORRESP | Letter to the SEC | Mar 15, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 13, 2024 | — |
| EFFECT | Filing | Aug 28, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 25, 2023 | — |
| CORRESP | Letter to the SEC | Aug 24, 2023 | — |
| EFFECT | Filing | Apr 10, 2023 | — |
| CORRESP | Letter to the SEC | Apr 7, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 6, 2023 | — |
| CORRESP | Letter to the SEC | Apr 6, 2023 | — |
| RW | Filing | Dec 12, 2022 | — |
| D | Filing | Jul 25, 2022 | — |
| DEFM14C | Filing | May 20, 2021 | — |
| PRER14C | Pre 14c | May 10, 2021 | — |
| PREM14C | Pre 14c | May 4, 2021 | May 4, 2021 |
| EFFECT | Filing | Feb 2, 2021 | — |
| CORRESP | Letter to the SEC | Feb 1, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 29, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 18, 2020 | — |
| EFFECT | Filing | Sep 17, 2020 | — |
| CERT | Filing | Sep 17, 2020 | — |
| CORRESP | Letter to the SEC | Sep 16, 2020 | — |
| CORRESP | Letter to the SEC | Sep 16, 2020 | — |
| 8-A12B | Filing | Aug 25, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 25, 2020 | — |
| RW | Filing | Feb 14, 2020 | — |
| NT 10-Q | Filing | Nov 14, 2019 | Sep 30, 2019 |
| CORRESP | Letter to the SEC | Nov 7, 2019 | — |
| CORRESP | Letter to the SEC | Nov 7, 2019 | — |
| CORRESP | Letter to the SEC | Nov 5, 2019 | — |
| CORRESP | Letter to the SEC | Nov 5, 2019 | — |
| CERT | Filing | Oct 18, 2019 | — |
| CORRESP | Letter to the SEC | Oct 4, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 3, 2019 | — |
| 8-A12B/A | Filing | Oct 2, 2019 | — |
| CORRESP | Letter to the SEC | Aug 12, 2019 | — |
| CERT | Filing | Aug 12, 2019 | — |
| CORRESP | Letter to the SEC | Aug 8, 2019 | — |
| CORRESP | Letter to the SEC | Aug 8, 2019 | — |
| 8-A12B | Filing | Aug 2, 2019 | — |
| CORRESP | Letter to the SEC | Jul 9, 2019 | — |
| AW | Filing | Jul 9, 2019 | — |
| RW WD | Filing | Jul 9, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2019 | — |
| RW | Registration withdrawal | Jul 1, 2019 | — |
| CORRESP | Letter to the SEC | Jun 28, 2019 | — |
| UPLOAD | Letter from the SEC | May 7, 2019 | — |
| EFFECT | Filing | Apr 23, 2019 | — |
| NT 10-K | Filing | Oct 2, 2018 | Jun 30, 2018 |
| NT 10-Q | Filing | Sep 28, 2018 | Jun 30, 2018 |
| D | Filing | Jul 10, 2018 | — |
| D | Filing | May 9, 2017 | — |
| EFFECT | Filing | Mar 30, 2017 | — |
| CORRESP | Letter to the SEC | Mar 28, 2017 | — |
| UPLOAD | Letter from the SEC | Feb 13, 2017 | — |
| D | Filing | Jan 19, 2017 | — |
| NT 10-Q | Form 12b-25 | Nov 15, 2016 | Sep 30, 2016 |
| D | Filing | Oct 26, 2016 | — |
| UPLOAD | Letter from the SEC | Jun 22, 2016 | — |
| PRER14A | Prer 14a | Jun 20, 2016 | — |
| UPLOAD | Letter from the SEC | Jun 16, 2016 | — |
| UPLOAD | Letter from the SEC | Jun 9, 2016 | — |
| CORRESP | Letter to the SEC | Jun 7, 2016 | — |
| CORRESP | Letter to the SEC | May 19, 2016 | — |
| NT 10-Q | Notification of late filing | May 13, 2016 | Mar 31, 2016 |
| UPLOAD | Letter from the SEC | May 12, 2016 | — |
| NT 10-K | Notification of late filing | Sep 28, 2015 | Jun 30, 2015 |
| 8-A12G | Form 8-a12g | Oct 14, 2014 | — |
| EFFECT | Filing | Nov 8, 2013 | — |
| CORRESP | Letter to the SEC | Nov 7, 2013 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2013 | — |
| UPLOAD | Letter from the SEC | Oct 2, 2013 | — |
| UPLOAD | Letter from the SEC | Sep 5, 2013 | — |
| D | Filing | Jul 2, 2013 | — |
Showing 94 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BIVI (Nasdaq), BIVIW (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- NV
- Headquarters
- Carson City, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1580149
- Former names
- NANOANTIBIOTICS, INC. (until Jul 22, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.